Study of SRN-101 before surgery for recurrent brain cancer
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called SRN-101 that is given directly into the brain tumor before surgery to remove it. The goal is to see if it is safe and could help people with a brain tumor that has come back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have already had standard treatment for your high-grade glioma (a type of brain cancer), which usually includes surgery plus radiation, with or without chemotherapy.
- You must have a single brain tumor that has come back (recurrent) and is planned for surgical removal. The tumor must be between 1 and 4 centimeters (less than 2 inches) and located in a part of the brain that is accessible.
- You should be able to take care of most of your daily tasks (a Karnofsky score of 70% or higher).
- At least 3 weeks must have passed since your last chemotherapy, 4 weeks since radiation, and 2 weeks since major surgery, and you should be recovered from any side effects.
- You must stop anticoagulant (blood-thinning) medication safely before the study drug is given, if you take any.
- If you have seizures, you need to be on a stable dose of anti-seizure medicine and not have had uncontrolled seizures in the last 3 months.
- You agree to long-term safety follow-up and must meet standard blood test requirements for organ function (bone marrow, liver, kidneys, clotting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.